sur Dogwood Therapeutics, Inc. (NASDAQ:DWTX)
Dogwood Therapeutics to Present at Maxim Growth Summit 2025
Dogwood Therapeutics, a biotechnology company listed on Nasdaq under the ticker DWTX, has announced its participation in the upcoming Maxim Growth Summit. The event is scheduled for October 22-23, 2025, at the Hard Rock Hotel in New York City. Greg Duncan, the company's CEO, will be available for discussions with institutional investors and senior analysts from Maxim Group LLC.
The company specializes in developing medicines for pain and neuropathic disorders. It focuses on two main programs: a non-opioid analgesic program and an antiviral program. Its lead candidate, Halneuron®, has shown promising results in reducing pain related to cancer and chronic chemotherapy-induced neuropathic pain.
The SP16 IV Phase 1b CINP trial, backed by the National Cancer Institute, aims to treat neuropathy and is expected to start enrolling patients in the first half of 2026.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Dogwood Therapeutics, Inc.